Quince Therapeutics stock (US74833Q1004): Nasdaq-listed biotech rebounds after regaining compliance

Quince Therapeutics shares on Nasdaq remained volatile after the rare-disease-focused biotech recently regained compliance with the exchange’s listing rules, keeping the United States-based stock listed while investors track its low market capitalization and ongoing strategic shift.

Quince Therapeutics shares continued to trade in low double-digit dollar territory on the Nasdaq in the United States after the biotechnology company recently confirmed that it had regained compliance with the exchange’s minimum bid-price rules, averting an immediate delisting risk according to a company announcement cited by Nasdaq on 05/2026. The stock, which trades under the ticker QNCX, has a market capitalization of around USD 17.9 million based on a last quoted price of about USD 1.10 per share as of late May 2026, according to MarketBeat data as of 05/27/2026. The listing remains centered on the US market, while German investors can access the stock via secondary venues such as Tradegate when liquidity is available.

According to price and performance data published by MarketBeat on 05/27/2026, Quince Therapeutics has seen its share price fall approximately 88.7 percent over the past 12 months and roughly 96 percent year-to-date, underlining how sensitive the small-cap biotech remains to news flow and funding expectations. Trading volumes have been elevated compared with the company’s size, with MarketBeat citing around 1.22 million shares changing hands at the latest close, reflecting ongoing repositioning by investors following the company’s strategic updates and the resolution of its compliance issue with Nasdaq.

On 05/27/2026, Investing.com showed Quince Therapeutics changing hands at about USD 1.15 on Nasdaq in regular trading, with a similar level indicated in pre-market quotations, signaling modest day-to-day moves but still leaving the stock deep below prior-year levels. These quotations underscore that, despite the regained compliance, the company’s equity value remains compressed and highly sensitive to news regarding its pipeline, business development, and financing. For German-based investors monitoring US small caps, the pricing in USD on Nasdaq remains the primary reference, even if occasional trading also occurs in euros on platforms such as Tradegate or Frankfurt.

MarketBeat’s news overview for Quince Therapeutics on late May 2026 highlights a company communication that it has “regained Nasdaq compliance,” which indicates that the stock previously fell below the exchange’s minimum USD 1 bid-price requirement but has since met the criteria again within the permitted cure period. Regaining compliance generally requires a sustained period with a closing bid at or above USD 1, typically measured over several consecutive trading days, and confirms that the exchange no longer considers QNCX at immediate risk of involuntary delisting based on that specific metric. For investors, this development removes an overhang that can weigh on small-cap biotech valuations and can impact liquidity, even though it does not alter the company’s fundamental clinical or financial profile.

Despite the relief on the listing front, Quince Therapeutics still trades at levels that keep it firmly in micro-cap territory on Nasdaq, which can lead to higher day-to-day volatility and wider spreads than larger biotech peers listed in the United States. According to MarketBeat’s performance summary as of 05/27/2026, the share price has moved only a few cents in recent sessions, but the long-term drawdown shows that previous announcements on pipeline strategy and capital allocation have not yet translated into a sustained re-rating. Investors in the US and in Germany who follow rare-disease and neurology-focused biotechs therefore continue to watch the company’s next clinical and corporate milestones closely.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Quince Therapeutics
• Sector/industry: Biotechnology, rare and debilitating diseases
• Headquarters/country: South San Francisco, United States
• Core markets: United States and other major pharmaceutical markets
• Key revenue drivers: Out-licensing, collaborations, and future product commercialization in rare and debilitating indications
• Home exchange/listing venue: Nasdaq Capital Market (QNCX)
• Trading currency: USD

Quince Therapeutics: core business model

Quince Therapeutics focuses on acquiring and advancing therapeutic candidates for patients with rare and debilitating conditions, aiming to unlock value primarily through development milestones, licensing deals, and eventual commercialization rather than a broad in-house sales infrastructure at this stage.

Valuation metrics and multiples for Quince Therapeutics

On a valuation basis, Quince Therapeutics is currently assessed largely on its cash position, pipeline prospects, and potential transaction optionality rather than on traditional earnings-based measures, as the company is still in a development-focused phase with limited or no recurring product revenue reported in recent filings. At a market capitalization of roughly USD 17.9 million on a share price of about USD 1.10 as reported by MarketBeat on 05/27/2026, the company’s equity value implies that any meaningful clinical success, partnership announcement, or asset sale could have an outsized impact on implied valuation compared with larger, more diversified biotech peers.

Conventional ratios such as price-to-earnings or EV/EBITDA are not yet meaningful for Quince Therapeutics because the business has not reported sustained positive earnings and continues to invest heavily in research and development. Instead, investors in the United States and abroad typically look at metrics such as market capitalization relative to cash on the balance sheet, the net present value of key pipeline assets, and comparable transactions in the rare-disease and neurology space to frame potential upside and downside scenarios. This makes the stock particularly sensitive to any updates around its clinical programs, licensing negotiations, and capital-raising plans, which can quickly shift market perceptions of fair value.

Conclusion

With its Nasdaq listing in the United States no longer under immediate pressure after regaining minimum bid-price compliance, Quince Therapeutics has removed a technical overhang that can weigh on micro-cap biotech valuations. At the same time, valuation remains low in absolute terms, with traditional earnings-based metrics offering limited guidance and investors instead focusing on balance sheet strength, clinical progress, and potential business-development catalysts. For both US and German investors following the stock, future updates on the pipeline and any partnering or transaction activity are likely to be key drivers of whether the share price can recover from the steep declines seen over the past year.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.